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Circulating long-non coding RNAs 
as biomarkers of left ventricular 
diastolic function and remodelling 
in patients with well-controlled 
type 2 diabetes
D. de Gonzalo-Calvo1,2, F. Kenneweg2, C. Bang2, R. Toro3, R. W. van der Meer4, L. J. Rijzewijk5, 
J. W. Smit6, H. J. Lamb4, V. Llorente-Cortes1,* & T. Thum2,7,8,*
Contractile dysfunction is underdiagnosed in early stages of diabetic cardiomyopathy. We evaluated 
the potential of circulating long non-coding RNAs (lncRNAs) as biomarkers of subclinical cardiac 
abnormalities in type 2 diabetes. Forty-eight men with well-controlled type 2 diabetes and 12 healthy 
age-matched volunteers were enrolled in the study. Left ventricular (LV) parameters were measured by 
magnetic resonance imaging. A panel of lncRNAs was quantified in serum by RT-qPCR. No differences in 
expression levels of lncRNAs were observed between type 2 diabetes patients and healthy volunteers. 
In patients with type 2 diabetes, long intergenic non-coding RNA predicting cardiac remodeling 
(LIPCAR) was inversely associated with diastolic function, measured as E/A peak flow (P < 0.050 for all 
linear models). LIPCAR was positively associated with grade I diastolic dysfunction (P < 0.050 for all 
logistic models). Myocardial infarction-associated transcript (MIAT) and smooth muscle and endothelial 
cell-enriched migration/differentiation-associated long noncoding RNA (SENCR) were directly 
associated with LV mass to LV end-diastolic volume ratio, a marker of cardiac remodelling (P < 0.050 
for all linear models). These findings were validated in a sample of 30 patients with well-controlled type 
2 diabetes. LncRNAs are independent predictors of diastolic function and remodelling in patients with 
type 2 diabetes.
Cardiovascular complications are the leading cause of morbidity and death in patients with diabetes1. Diabetes 
affects cardiac structure and function in the absence of other comorbidities such as coronary disease or hyper-
tension, a condition known as diabetic cardiomyopathy2. In recently diagnosed patients with well-controlled and 
uncomplicated type 2 diabetes, contractile dysfunction and adverse cardiac remodelling are subclinical events 
preceding the development of symptomatic heart failure (HF)3,4. We have demonstrated that intervention strat-
egies could improve cardiac function in stable diabetic patients5. However, the detection of diabetic cardiomy-
opathy remains a challenge due to the absence of clinical symptoms in preclinical disease stages and the limited 
availability and relatively high costs of cardiac imaging techniques. Regular screening approaches could benefit 
from accurate, accessible and easy-to-apply diagnostic tools that expand current technologies used to detect early 
signs of cardiac alterations. As such, the development of diagnostic blood tests to predict and/or monitor cardiac 
abnormalities in type 2 diabetes patients is a key area of interest in the field of diabetes research.
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Long non-coding RNAs (lncRNAs) are transcripts longer that 200 nucleotides that function as epigenetic 
regulators of gene expression6. Several lines of evidence indicate that lncRNAs play an essential role in cardiac 
development, function and disease7,8. Recent studies have proposed that lncRNAs can be used as cardiac bio-
markers9,10. LncRNAs are highly cell- and context-specific, their expression correlates with cardiac status in both 
normal and pathological conditions and they can be detected in the extracellular fluids of patients11,12. Indeed, 
pioneering investigations recently identified circulating lncRNAs as useful diagnostic and prognostic biomark-
ers of cardiac remodelling and cardiovascular death13,14. Previous studies have examined the role of lncRNAs in 
diabetes-related cardiovascular complications in vitro, in vivo and in biopsied human tissue15,16. Little is known 
about the potential of circulating lncRNAs as indicators of diabetes and associated cardiovascular complica-
tions17. Here, we investigated for the first time the potential value of circulating lncRNAs as biomarkers of early 
cardiac alterations in patients with well-controlled type 2 diabetes. To this end, we evaluated a panel of lncRNAs 
directly involved in cardiovascular disease and/or diabetic conditions and their relationship with magnetic res-
onance imaging (MRI) indices of cardiac dimensions and function, in serum from patients with well-controlled 
type 2 diabetes of short duration.
Results
Circulating lncRNAs in type 2 diabetes patients and healthy controls. The clinical characteristics 
of the 60 participants included in the initial study are summarized in Table 1. A total of 48 type 2 diabetes patients 
and 12 age-matched healthy volunteers were enrolled. Body mass index (BMI) and systolic blood pressure (SBP) 
were higher in type 2 diabetes patients with respect to controls.
LncRNA analysis was performed on RNA derived from the serum of all type 2 diabetes patients and healthy 
volunteers. Long intergenic non-coding RNA predicting cardiac remodeling (LIPCAR), uc004cos.4, uc004cov.4, 
uc004coz.1, uc011mfi.2, uc022bqu.1, uc022bqw.1, HOX transcript antisense RNA (HOTAIR) and myocardial 
infarction-associated transcript (MIAT) were consistently amplified in all individual samples. H19 was below 
the limit of detection in 10% and 17% of type 2 diabetes and control samples, respectively. Smooth muscle and 
endothelial cell-enriched migration/differentiation-associated long noncoding RNA (SENCR) was below the 
limit of detection in 2% and 8% of type 2 diabetes and control samples, respectively. Both lncRNAs were used 
in further analyses. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) levels were below the 
limit of detection in 65% and 75% of type 2 diabetes and control samples, respectively and this lncRNA was 
excluded from further analyses. Circulating levels of LIPCAR, uc004cos.4, uc004cov.4, uc004coz.1, uc011mfi.2, 
uc022bqu.1 and uc022bqw.1 were positively correlated with one other in both study groups (Supplementary  
Tables S1 and S2). A close correlation between circulating H19, HOTAIR, MIAT and SENCR levels was also 
observed in the type 2 diabetes group.
We next compared expression levels of lncRNAs in circulating from type 2 diabetes patients and age-matched 
healthy controls (Supplementary Figure S1). Levels of uc011mfi.2, uc022bqu.1, uc022bqw.1 were lower in type 2 
diabetes patients as compared with healthy volunteers (P < 0.050 for all comparisons). In contrast, levels of MIAT 
were higher in type 2 diabetes patients as compared with healthy volunteers (P < 0.050). Nonetheless, no statisti-
cal differences in uc011mfi.2, uc022bqu.1, or uc022bqw.1 were observed between study groups after accounting 
for differences in BMI (P > 0.050 for all comparisons). No statistical differences in MIAT levels were detected 
between groups after adjusting for differences in BMI and SBP (P > 0.050).
Association between circulating lncRNAs and left ventricular dimension and function param-
eters in patients with type 2 diabetes. Univariate linear regression analysis was performed to explore 
the associations between cardiac MRI markers of left ventricular (LV) dimension and function and circulating 
lncRNA levels (Table 2). Type 2 diabetes patients showed a significant association between indices of LV diastolic 
function and lncRNA expression levels. Positive associations were observed between: i) E-decpeak and LIPCAR, 
uc004cos.4, uc004cov.4, uc004coz.1, uc022bqw.1 and SENCR; and ii) E-decmean and LIPCAR, uc004cos.4, 
uc004cov.4, uc004coz.1, uc011mfi.2, uc022bqu.1, uc022bqw.1 and SENCR. Inverse associations were observed 
between: i) E peak filling rate and LIPCAR; and ii) E/A peak flow ratio and LIPCAR, uc004cos.4, uc004cov.4, 
uc004coz.1, c011mfi.2, uc022bqu.1 and uc022bqw.1. As regards cardiac structure, LVMV-ratio was positively 
associated with MIAT and SENCR expression. No significant association was observed between either H19 or 
HOTAIR and any of the parameters of LV diastolic function and structure analysed (P > 0.050 for all associa-
tions). There were no associations identified between circulating lncRNA levels and LV dimension, systolic func-
tion, or myocardial steatosis, except for MIAT, which showed a weak inverse association with LV end-diastolic 
volume in type 2 diabetes patients. In healthy volunteers, no association between cardiac MRI parameters and 
circulating lncRNA levels was observed (P > 0.050 for all associations).
Association between circulating lncRNAs and clinical characteristics in type 2 diabetes 
patients. To further explore the potential of circulating lncRNAs as predictors of cardiac dimensions and 
function, we evaluated the extent to which lncRNA levels were influenced by clinical characteristics in type 2 
diabetes patients (Table 3). HDL-C and time since diagnosis of diabetes were positively associated with expres-
sion levels of the mitochondrial-derived lncRNAs LIPCAR, uc004cos.4, uc004cov.4, uc004coz.1, uc011mfi.2, 
uc022bqu.1 and uc022bqw.1. By contrast, expression levels of these same lncRNAs were inversely associated 
with BMI, waist circumference, plasma fasting insulin and subcutaneous fat volume. Age was positively asso-
ciated with levels of LIPCAR, uc004cos.4, uc004cov.4 and uc022bqw.1. us-CRP was negatively associated with 
LIPCAR, uc004cov.4, uc011mfi.2, uc022bqu.1 and uc022bqw.1 expression. No association was detected between 
any other clinical characteristics and the expression of these lncRNAs. There was no significant association 
between H19, HOTAIR, MIAT and SENCR and any of the clinical characteristics studied (P > 0.050 for all asso-
ciations). Circulating levels of the lncRNAs analysed were not significantly associated with the use of statins, 
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antihypertensive medication, β -blockers, diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin 
receptor blockers (ARBs), or calcium antagonists (P > 0.050 for all associations).
Circulating LIPCAR is an independent predictor of left ventricular diastolic function in patients 
with type 2 diabetes. E/A peak flow was used as measure of LV diastolic function for further analyses18–20. 
Given that expression levels of LIPCAR, uc004cos.4, uc004cov.4, uc004coz.1, uc011mfi.2, uc022bqu.1 and 
uc022bqw.1 were positively correlated with each other, we selected LIPCAR, the lncRNA most strongly associated 
with E/A peak flow, for subsequent statistical analysis.
Multivariate analysis was performed to explore in detail the relationship between LV diastolic function and 
LIPCAR levels in patients with well-controlled type 2 diabetes of short duration (Table 4). To this end, E/A 
peak flow was entered as a dependent variable and age, BMI and LIPCAR expression were entered as inde-
pendent variables (model 1). Neither age nor BMI had any effect on the association between E/A peak flow 
and LIPCAR. Time since diagnosis of diabetes, plasma fasting insulin, HDL-C and us-CRP, all of which were 
significantly associated with circulating LIPCAR levels in univariate analysis, and plasma fasting glucose, myo-
cardial steatosis, SBP, diastolic blood pressure (DBP) and heart rate, which have been previously associated with 
diastolic function19, were separately entered as independent variables into model 1 (model 2), in order to take 
into account the potential confounding effect of these variables on the associations observed. The established 
clinical biomarker NT-proBNP was also entered separately as an independent variable into the same model for 
a more detailed study of circulating lncRNAs as potential biomarker. Adjustment for different clinical, biochem-
ical, or metabolic variables had no effect on the association between diastolic function and circulating LIPCAR 
levels. To gain further insight into the association between LV diastolic function and LIPCAR we compared 
E/A peak flow levels in patients in the highest quartile of LIPCAR expression with those in all other quartiles 
(Supplementary Figure S2A). E/A peak flow levels were significantly lower in patients in the highest quartile 
compared with those in quartiles 1, 2 and 3 (P < 0.050).
Given the observed association between LV diastolic function parameters and LIPCAR, uc004cos.4, 
uc004cov.4, uc004coz.1, c011mfi.2, uc022bqu.1 and uc022bqw.1 expression levels, we hypothesized that circu-
lating levels of these lncRNAs could constitute potential biomarkers of LV diastolic impairment in patients with 
Variable




P-valueN = 48 N = 12
Age (years) 57.5 ± 5.4 57.7 ± 6.7 0.940
Time since diagnosis of diabetes (years) 4.0 ± 2.5 —
Body mass index (kg/m2) 29.2 ± 3.5 26.8 ± 2.1 0.005*
Waist circumference (cm) 106.4 ± 9.8 98.8 ± 8.9 0.021*
Subcutaneous fat volume (mL) 706.6 ± 248.4 558.6 ± 209.7 0.063
Visceral fat volume (mL) 444.65 ± 206.6 324.5 ± 125.2 0.060
Systolic blood pressure (mm Hg) 128.1 ± 12.2 112.6 ± 9.3 < 0.001*
Diastolic blood pressure (mmHg) 75.9 ± 6.1 76.2 ± 9.0 0.931
Heart rate (bpm) 65.7 ± 8.5 61.1 ± 9.8 0.082
Concomitant medication N (%)
 Statin 25 (52.1) —
 Any antihypertensive medication 21 (43.8) —
 β -Blocker 6 (12.5) —
 Diuretic 11 (22.9) —
 ACE inhibitor 10 (20.8) —
 ARB 5 (10.4) —
 Calcium antagonist 3 (6.3) —
HbA1c (%) 7.2 ± 1.0 —
Plasma fasting glucose (mmol/L) 9.0 ± 2.1 5.3 ± 0.4 < 0.001*
Plasma fasting insulin (pmol/L) 66.8 ± 35.4 42.6 ± 22.2 0.009*
Total cholesterol (mmol/L) 4.6 ± 0.9 5.1 ± 0.5 0.114
LDL cholesterol (mmol/L) 2.7 ± 0.8 3.3 ± 0.5 0.022*
HDL cholesterol (mmol/L) 1.1 ± 0.3 1.3 ± 0.2 0.057
Plasma triglycerides (mmol/L) 1.8 ± 1.1 1.1 ± 0.5 0.017*
Plasma NEFA (mmol/L) 0.5 ± 0.2 0.5 ± 0.2 0.990
us-CRP (mg/L) 5.3 ± 4.2 6.3 ± 3.7 0.261
NT-proBNP (ng/L) 38.4 ± 29.8 36.6 ± 24.2 0.952
Table 1.  Characteristics of the study population. Data are presented as mean ± SD for continuous variables 
and as frequencies (percentages) for categorical variables. *Statistically significant. ACE: Angiotensin-
converting enzyme; ARB: angiotensin receptor blocker; HbA1c: Glycated haemoglobin. For other abbreviations 
see the text.
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stable type 2 diabetes. We stratified the type 2 diabetes population according to current recommendations for 
LV diastolic function21, thus forming 2 groups: type 2 diabetes patients with normal diastolic function (N = 24) 
and type 2 diabetes patients with grade I diastolic dysfunction (N = 24). The prevalence of diastolic dysfunc-
tion (50%) was comparable with that reported in previous studies2. Univariate logistic regression revealed that 
LIPCAR, uc004cos.4, uc004cov.4, uc004coz.1, c011mfi.2, uc022bqu.1 and uc022bqw.1 were predictors of grade I 
diastolic dysfunction (Table 5). LIPCAR was most strongly associated with LV diastolic function parameters and 
was thus used in further analyses. Multivariate logistic regression models identified LIPCAR as an independent 
predictor of grade I diastolic dysfunction in patients with type 2 diabetes, even after adjusting for age and BMI 
(model 1) and other potential confounding factors (model 2) (Table 5). The models showed good discrimination: 
area under the ROC curve (AUC) from 0.745 (0.559, 0.891) to 0.842 (0.725, 0.959) (Supplementary Table S3). 
Furthermore, type 2 diabetes patients with abnormal diastolic dysfunction showed higher levels of LIPCAR as 
compared with patients with normal diastolic function (P < 0.050) (Supplementary Figure S2B). Neither E/A 
peak flow nor grade I diastolic dysfunction were associated with levels of the established biomarkers NT-proBNP 
or us-CRP (P > 0.050 for all associations).
Circulating MIAT and SENCR as independent predictors of left ventricular remodelling in 
patients with type 2 diabetes. Univariate linear regression analysis revealed a strong association between 
LVMV-ratio and circulating MIAT and SENCR levels. To further assess the potential of these lncRNAs as 
predictors of LV remodelling, the association between LVMV-ratio and circulating MIAT and SENCR levels 
was explored using multivariate linear regression models (Table 6). In model 1, LVMV-ratio was entered as a 
mean ± SD
LIPCAR uc004cos.4 uc004cov.4 uc004coz.1 uc011mfi.2 uc022bqu.1 uc022bqw.1 MIAT SENCR
β P-value β P-value β P-value β P-value β P-value β P-value β P-value β P-value β P-value
LV dimensions
 LV mass (g) 108.1 ± 18.2 − 0.088 0.556 − 0.111 0.464 − 0.162 0.283 − 0.205 0.167 − 0.197 0.179 − 0.163 0.275 − 0.176 0.236 0.072 0.626 0.170 0.248
 LV end-systolic volume (mL) 61.1 ± 14.3 − 0.038 0.799 − 0.103 0.496 − 0.067 0.660 − 0.114 0.444 − 0.086 0.563 − 0.025 0.867 − 0.040 0.788 − 0.220 0.132 − 0.238 0.104
 LV end-diastolic volume (mL) 155.7 ± 24.9 − 0.149 0.316 − 0.191 0.204 − 0.179 0.234 -0.200 0.177 − 0.156 0.288 − 0.135 0.364 − 0.170 0.253 − 0.289 0.046* − 0.236 0.107
 LVMV-ratio (g/mL) 0.7 ± 0.1 0.058 0.696 0.067 0.656 0.006 0.969 − 0.011 0.940 − 0.031 0.836 − 0.035 0.813 − 0.004 0.977 0.376 0.008* 0.375 0.009*
LV systolic function
 LV Stroke volume (mL) 94.6 ± 17.1 − 0.186 0.210 − 0.189 0.209 − 0.202 0.179 − 0.196 0.188 − 0.157 0.288 − 0.176 0.235 − 0.214 0.149 − 0.238 0.104 − 0.146 0.324
 LV Ejection Fraction (%) 60.8 ± 5.8 − 0.059 0.694 − 0.001 0.994 − 0.046 0.762 0.012 0.935 0.010 0.947 − 0.068 0.650 − 0.077 0.606 0.036 0.810 0.101 0.494
 Cardiac index (L/min * m−2) 3022 ± 540 − 0.058 0.697 − 0.131 0.386 − 0.117 0.440 − 0.081 0.587 0.009 0.954 − 0.057 0.705 − 0.039 0.793 − 0.165 0.262 − 0.152 0.302
LV diastolic function
 E peak filling rate (mL/s) 419.5 ± 82.6 − 0.296 0.044* − 0.259 0.082 − 0.262 0.078 − 0.272 0.064 − 0.185 0.209 − 0.245 0.096 − 0.256 0.082 − 0.181 0.218 − 0.234 0.110
 E-decpeak (mL/s2 *10−3) − 3.5 ± 1.0 0.335 0.022* 0.316 0.032* 0.334 0.023* 0.315 0.031* 0.266 0.067 0.279 0.058 0.300 0.040* 0.152 0.301 0.432 0.002*
 E− decmean (mL/s2 *10−3) − 2.3 ± 0.6 0.459 0.001* 0.432 0.003* 0.435 0.003* 0.422 0.003* 0.338 0.019* 0.408 0.004* 0.422 0.003* 0.154 0.296 0.320 0.027*
 E/A peak flow 1.0 ± 0.2 − 0.413 0.004* − 0.366 0.012* − 0.381 0.009* − 0.338 0.020* -0.333 0.021* − 0.355 0.014* − 0.380 0.008* − 0.118 0.423 − 0.264 0.070
 E/Ea 9.3 ± 3.4 0.022 0.891 0.092 0.563 0.083 0.608 0.070 0.660 − 0.032 0.837 0.140 0.378 0.147 0.354 0.142 0.365 − 0.108 0.489
Myocardial steatosis
 Neutral lipid content (%) 0.9 ± 0.4 0.010 0.945 0.062 0.683 0.051 0.737 0.146 0.327 0.110 0.456 − 0.014 0.927 − 0.037 0.803 0.023 0.875 0.132 0.371
Table 2.  Associations between parameters of cardiac dimensions and function and circulating lncRNAs in 
patients with well-controlled type 2 diabetes. *Statistically significant. A: Atrial contraction; E: Early diastolic 
filling phase; E/Ea: Estimation of left ventricular filling pressures; LV: Left ventricular; LVMV: Left ventricular 
mass/left ventricular end-diastolic volume.
LIPCAR uc004cos.4 uc004cov.4 uc004coz.1 uc011mfi.2 uc022bqu.1 uc022bqw.1 MIAT SENCR
β P-value β P-value β P-value β P-value β P-value β P-value β P-value β P-value β P-value
Age 0.372 0.010* 0.380 0.009* 0.304 0.040* 0.239 0.106 0.184 0.210 0.277 0.060 0.370 0.011* 0.165 0.261 0.162 0.271
Time since diagnosis 
of diabetes 0.373 0.010* 0.407 0.005* 0.375 0.010* 0.347 0.017* 0.289 0.047* 0.319 0.029* 0.301 0.040* − 0.071 0.633 0.190 0.195
BMI − 0.448 0.002* − 0.380 0.009* − 0.434 0.003* − 0.360 0.013* − 0.416 0.003* − 0.409 0.004* − 0.438 0.002* − 0.161 0.276 0.012 0.934
Waist circumference − 0.459 0.001* − 0.431 0.003* − 0.483 0.001* − 0.429 0.003* − 0.469 0.001* − 0.448 0.002* -0.458 0.001* − 0.205 0.162 − 0.001 0.995
Subcutaneous fat 
volume − 0.491 < 0.001* − 0.416 0.004* − 0.453 0.002* − 0.404 0.005* − 0.462 0.001* − 0.453 0.001* − 0.468 0.001* − 0.168 0.255 − 0.024 0.874
Plasma fasting insulin − 0.548 < 0.001* − 0.468 0.001* − 0.472 0.001* − 0.441 0.002* − 0.527 < 0.001* − 0.475 0.001* − 0.499 < 0.001* − 0.165 0.268 0.067 0.654
HDL cholesterol 0.441 0.002* 0.337 0.023* 0.314 0.036* 0.299 0.043* 0.377 0.009* 0.342 0.020* 0.347 0.018* 0.122 0.413 − 0.090 0.547
us− CRP − 0.307 0.038* − 0.271 0.071 − 0.297 0.048* − 0.245 0.100 − 0.317 0.030* − 0.334 0.023* − 0.308 0.037* − 0.148 0.321 − 0.031 0.834
Table 3. Associations between clinical characteristics and circulating lncRNAs in patients with well-
controlled type 2 diabetes. *Statistically significant.
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dependent variable and age, BMI and MIAT or SENCR levels as independent variables. The following possi-
ble confounders were separately entered as independent variables into model 1 (model 2): plasma fasting glu-
cose, plasma fasting insulin, time since diagnosis of diabetes, heart rate, SBP, DBP, myocardial steatosis, us-CRP 
and NT pro-BNP. Circulating MIAT levels were independently associated with LVMV-ratio after adjusting 
for all confounders. Similar results were obtained for SENCR. Type 2 diabetes patients in the fourth quartile 
of circulating MIAT or SENCR levels showed a higher LVMV-ratio than those in lower quartiles (P < 0.050) 
(Supplementary Figure S2C). No association was observed between LVMV-ratio and levels of NT-proBNP or 
us-CRP (P > 0.050 for all associations).
Validation study. Circulating levels of LIPCAR, SENCR and MIAT were further evaluated in a validation 
study of 30 men with well-controlled type 2 diabetes (Table 7). In agreement with the findings presented above, 
type 2 diabetes patients showed a significant association between the index of LV diastolic function E/A peak 
flow and circulating LIPCAR expression levels (Table 8). As expected, E/A peak flow levels were significantly 
lower in patients in the third tertile compared with those in tertiles 1 and 2 (Supplementary Figure S3A). A direct 
association between LVMV-ratio and circulating MIAT and SENCR levels was also observed in the validation 
study (Table 8). Furthermore, patients in the third tertile of circulating MIAT or SENCR levels showed a higher 
LVMV-ratio than those in lower tertiles (Supplementary Figure S3B). Finally, confirming the results of our initial 
study, no association was observed between E/A peak flow, grade I diastolic dysfunction or LVMV-ratio and lev-
els of NT-proBNP or us-CRP in the validation study (P > 0.050 for all associations).
Discussion
In a population-based study of patients with well-controlled type 2 diabetes, we demonstrated that circulating 
lncRNA levels are independent predictors of LV diastolic function and remodelling. To our knowledge this is the 
first study to investigate the potential of circulating lncRNAs as biomarkers of cardiovascular complications in 
diabetes.
Previous studies have produced evidence of subclinical LV diastolic dysfunction and adverse LV concentric 
remodelling in patients with uncomplicated type 2 diabetes22,23. Both conditions are preclinical events in the 
pathophysiology of diabetic cardiomyopathy that are intimately associated with adverse cardiovascular prognosis, 
including cardiovascular death23. Improvement in LV compliance could be achieved through the implementation 
of therapeutic interventions, particularly in subclinical stages of the disease5. However, the diagnosis of early car-
diac dysfunction in type 2 diabetes remains challenging. The identification of novel blood biomarkers with which 
to monitor diastolic function and cardiac remodelling is of major clinical importance for the correct management 
of diabetic patients. Non-coding RNA-based approaches provide new opportunities to develop novel biomarkers. 
Small RNAs such as microRNAs (miRNAs) have been proposed as sensitive and specific biomarkers of cardio-
vascular disease24,25. Extracellular lncRNAs are potent biomarkers in cancer26. Indeed, assays with clinical appli-
cation have been developed for the detection of urine PCA3, a lncRNA reported to be a highly specific biomarker 
of prostate cancer27. Nonetheless, no previous study has investigated the potential use of circulating lncRNAs 
as indicators of early cardiac abnormalities in type 2 diabetes. We evaluated a panel of lncRNAs implicated in 
cardiovascular disease and/or diabetic conditions in relation with a wide range of measures of LV dimension and 
function in asymptomatic patients with well-controlled type 2 diabetes. First, we found that expression levels of 
all mitochondrial-derived lncRNAs evaluated were inversely correlated with parameters of LV diastolic function, 
with the strongest association observed for LIPCAR. Circulating LIPCAR levels were inversely correlated with 
β P-value
Model 1
 LIPCAR − 0.427 0.010*
 Age − 0.192 0.191
 BMI − 0.190 0.212
Model 2
Association between E/A peak flow and circulating LIPCAR for 
model 1 and each of following variables:
 Plasma fasting glucose − 0.460 0.006*
 Plasma fasting insulin − 0.436 0.018*
 Time since diagnosis of diabetes − 0.423 0.015*
 Myocardial Steatosis − 0.427 0.011*
 HDL cholesterol − 0.372 0.034*
 SBP − 0.442 0.008*
 DBP − 0.386 0.021*
 Heart rate − 0.480 0.004*
 us-CRP − 0.399 0.024*
 NT-proBNP − 0.448 0.009*
Table 4.  Association between LV diastolic function and circulating LIPCAR in patients with well-
controlled type 2 diabetes. *Statistically significant.
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the marker of LV diastolic function E/A peak flow, independently of possible confounders. Using a different 
approach, we demonstrated that LIPCAR is an independent predictor of grade I diastolic dysfunction in patients 
with no clinically detectable cardiac alterations. These results confirm and expand upon previous findings iden-
tifying circulating LIPCAR as a biomarker of chronic HF or adverse outcome after MI13. Second, the direct asso-
ciation of LVMV-ratio with circulating MIAT and SENCR, even after adjusting for possible confounding factors, 
indicates that both lncRNAs are independent predictors of LV remodelling in patients with stable type 2 diabetes. 
Corroborating these associations, higher LVMV-ratios, indicating increased LV concentric remodelling, were 
found in patients in the highest quartiles of MIAT and SENCR expression. Validation studies in a second popu-
lation of patients with type 2 diabetes confirmed these findings. Interestingly, the association between circulating 
lncRNAs and LV function and remodelling appears to be specific to type 2 diabetes patients, as no such correla-
tion was observed for the control group. Our data demonstrate that circulating levels of LIPCAR and MIAT or 
SENCR may constitute novel biomarkers of LV diastolic function and remodelling, respectively, in patients with 
well-controlled type 2 diabetes.
Exploration of the associations between of LV dimension and function parameters and existing cardiovascular 
biomarkers, such as NT-proBNP and us-CRP, revealed additional value of circulating lncRNAs as biomarkers. 
Neither of the 2 biomarkers were associated with LV function or remodelling parameters. The potential clinical 
utility of lncRNAs was thus superior to that of available cardiac biomarkers. Furthermore, the association between 
LV diastolic function and remodelling and the lncRNAs analysed revealed remarkable stability after adjustment 
for other predictors. These findings indicate that lncRNAs provide additional information over standard clinical 
diagnostic tests in asymptomatic type 2 diabetes patients.
Mitochondria-derived lncRNAs were associated with age, body composition parameters, metabolic param-
eters and inflammation. Specifically, LIPCAR was strongly correlated with waist circumference, plasma fasting 
insulin, subcutaneous fat volume and HDL-C. These results suggest that LIPCAR levels are associated with met-
abolic homeostasis, which could limit its value as a specific biomarker of cardiac impairment. Nonetheless, as 
noted previously, these clinical characteristics had no influence on the independent relationship between LV dias-
tolic function and LIPCAR expression. Notably, MIAT and SENCR levels were not correlated with other clinical, 
biochemical, or metabolic parameters, supporting the use of these lncRNAs as biomarkers of LV remodelling.
OR (95% IC) P-value
Univariate analysis
 LIPCAR 1.047 (1.008, 1.087) 0.017*
 uc004cos.4 1.033 (1.006, 1.062) 0.018*
 uc004cov.4 1.172 (1.027, 1.337) 0.018*
 uc004coz.1 1.040 (1.004, 1.077) 0.027*
 uc011mfi.2 1.107 (1.019, 1.203) 0.017*
 uc022bqw.1 1.043 (1.006, 1.082) 0.022*
 uc022bqu.1 1.049 (1.008, 1.093) 0.020*
 H19 1.959 (0.469, 9.178) 0.356
 HOTAIR 1.067 (0.904, 1.259) 0.446
 MIAT 0.890 (0.170, 4.666) 0.890
 SENCR 1.673 (0.119, 3.545) 0.703
Multivariate analysis
Model 1
  LIPCAR 1.053 (1.007, 1.101) 0.023*
  Age 1.090 (0.957, 1.240) 0.195
  BMI 1.171 (0.938, 1.462) 0.163
Model 2
Association between LV diastolic dysfunction and circulating LIPCAR for 
model 1 and each of following variables:
 Plasma fasting glucose 1.058 (1.008, 1.111) 0.022*
 Plasma fasting insulin 1.046 (1.002, 1.091) 0.040*
 Time since diagnosis of diabetes 1.048 (1.003, 1.094) 0.034*
 Myocardial Steatosis 1.054 (1.007, 1.103) 0.024*
 HDL cholesterol 1.049 (1.005, 1.095) 0.030*
 SBP 1.053 (1.007, 1.101) 0.022*
 DBP 1.052 (1.006, 1.100) 0.025*
 Heart rate 1.056 (1.008, 1.106) 0.021*
 us-CRP 1.045 (1.001, 1.091) 0.044*
 NT-proBNP 1.064 (1.013, 1.118) 0.013*
Table 5.  Association between LV diastolic dysfunction and circulating lncRNAs in patients with well-
controlled type 2 diabetes. OR: Odds Ratio, CI: Confidence Interval. *Statistically significant.
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Importantly, no differences in circulating expression levels of lncRNAs were observed between diabetic 
and non-diabetic participants. Although unadjusted analyses revealed contrasting uc011mfi.2, uc022bqu.1, 
uc022bqw.1 and MIAT levels between groups, these differences did not persist after adjusting for body composi-
tion and blood pressure and were thus attributable to divergent clinical characteristics between groups.
We can only speculate as to the biological implications of the associations observed. The association between 
LV function and remodelling and circulating levels of lncRNAs in type 2 diabetes patients with verified absence 
of structural heart disease or cardiac ischemia, even after adjustment for possible confounding factors, suggests 
that circulating levels of these lncRNAs may be at least in part linked to diabetic cardiomyopathy or related 
conditions. Mitochondrial dysfunction is implicated in the aetiology of diabetic cardiomyopathy28 and transcrip-
tional profiling has revealed an abundance of mitochondria-derived lncRNAs in human LV samples10. Both these 
observations support the close correlation described here between circulating LIPCAR levels and LV diastolic 
dysfunction in type 2 diabetes patients. In addition, the association observed between both MIAT and SENCR, 
which are implicated in vascular conditions16,29 and LVMV-ratio, a marker of cardiac remodelling, is consistent 
with the reported relationship between microvascular dysfunction and LV cardiac remodelling30. Indeed, micro-
vascular alterations could not be excluded by dobutamine stress echocardiography in our study participants19.
Strengths of our study are the considerable number of patients/subjects that have been analysed using MRI 
and the control of potential confounding factors, including structural disease and ischemia. Some limitations of 
the present study should be noted. First, generalization of the results is somewhat limited by the defining char-
acteristics of the type 2 diabetes population: men with well-controlled disease and no significant comorbidities. 
Second, the panel of lncRNAs examined is biased by subjective selection. Future studies using global transcrip-
tomics analyses will identify novel lncRNAs with potential as biomarkers of diabetes-related cardiac compli-
cations. Third, despite the robustness of the associations observed here a larger sample size would have been 
desirable. The strict inclusion and exclusion criteria, as well as the techniques used (e.g. MRI) limited the sample 
size. Fourth, our findings need to be validated in larger independent populations. Fifth, we could not determine 
whether the observed associations imply causal relationships. Sixth, our data do not allow us to identify the tissue 
origin of circulating lncRNAs. Seventh, the biological role of these lncRNAs in cardiac physiology or pathology 
remains unknown. Finally, a synthetic exogenous miRNA derived from Caenorhabditis elegans, cel-miR-39, was 
used as internal control. Differences related to RNA size during RNA isolation should be taken into account. 
There is a lack of accepted internal standards for extracellular non-coding RNAs, including lncRNAs. The use of 
different methods (e.g. lncRNAs with stable expression, lncRNAs lacking sequence homology to human lncRNAs 
spiked in the samples or the Ct average, among others) should improve the normalization of the data31.
Despite these limitations, our study provides the first insight into the potential value of circulating lncR-
NAs as indicators of cardiovascular conditions in patients with type 2 diabetes. We demonstrate that circulating 
lncRNAs are independent predictors of LV diastolic function and remodelling in asymptomatic patients with 
well-controlled type 2 diabetes. Circulating lncRNAs thus emerge as promising biomarkers of preclinical LV 
impairment in diabetic cardiomyopathy. A simple blood test based on LIPCAR, MIAT and SENCR could serve as 
a useful early diagnostic tool for the assessment of LV diastolic function and remodelling in patients with type 2 
diabetes. Additional studies are required to validate these findings and provide further data into the potential role 
of circulating lncRNAs as biomarkers of cardiac complications in type 2 diabetes.
Methods
Subjects. Clinical and demographic data on all patients participating in the present study have been pre-
viously published as part of the PIRAMID (Pioglitazone Influence on triglyceride Accumulation in the 
β P-value β P-value
Model 1 Model 1
MIAT 0.396 0.005* SENCR 0.345 0.015*
Age 0.172 0.211 Age 0.168 0.233
BMI 0.305 0.029* BMI 0.236 0.092
Model 2 Model 2
Association between LVMV-ratio and circulating 
MIAT for model 2 and each of following variables:
Association between LVMV-ratio and circulating 
SENCR for model 2 and each of following variables:
Plasma fasting glucose 0.411 0.005* Plasma fasting glucose 0.353 0.015*
Plasma fasting insulin 0.425 0.003* Plasma fasting insulin 0.333 0.021*
Time since diagnosis of 
diabetes 0.404 0.005*
Time since diagnosis of 
diabetes 0.357 0.014*
SBP 0.385 0.007* SBP 0.334 0.019*
DBP 0.375 0.008* DBP 0.323 0.023*
Heart rate 0.390 0.006* Heart rate 0.340 0.017*
Myocardial steatosis 0.396 0.006* Myocardial steatosis 0.349 0.015*
NT-proBNP 0.401 0.005* NT-proBNP 0.365 0.011*
us-CRP 0.389 0.008* us-CRP 0.348 0.018*
Table 6.  Association between LV remodelling and circulating lncRNAs in patients with well-controlled 
type 2 diabetes. *Statistically significant.
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Variable
Type 2 diabetes Patients
N = 30
Age (years) 55.0 ± 5.7
Time since diagnosis of diabetes (years) 4.3 ± 2.9
Body mass index (kg/m2) 28.0 ± 3.3
Waist circumference (cm) 101.1 ± 10.2
Subcutaneous fat volume (mL) 648.7 ± 272.6
Visceral fat volume (mL) 422.8 ± 207.8
Systolic blood pressure (mm Hg) 126.9 ± 11.0
Diastolic blood pressure (mmHg) 75.4 ± 8.6
Heart rate (bpm) 64.9 ± 9.4
Concomitant medication N (%)
 Statin 12 (40.0)
 Any antihypertensive medication 13 (43.3)
 β -Blocker 1 (3.3)
 Diuretic 1 (3.3)
 ACE inhibitor 8 (26.7)
 ARB 4 (13.3)
 Calcium antagonist 1 (3.3)
HbA1c (%) 7.0 ± 1.0
Plasma fasting glucose (mmol/L) 7.8 ± 1.3
Plasma fasting insulin (pmol/L) 79.7 ± 45.6
Total cholesterol (mmol/L) 4.9 ± 1.2
LDL cholesterol (mmol/L) 2.8 ± 0.8
HDL cholesterol (mmol/L) 1.1 ± 0.3
Plasma triglycerides (mmol/L) 2.3 ± 2.8
Plasma NEFA (mmol/L) 0.5 ± 0.2
us-CRP (mg/L) 12.8 ± 29.3
NT-proBNP (ng/L) 30.9 ± 21.7
Parameters of cardiac dimensions and function
 LV mass (g) 106.1 ± 14.3
 LV end-systolic volume (mL) 65.5 ± 14.8
 LV end-diastolic volume (mL) 157.6 ± 25.1
 LVMV-ratio (g/mL) 0.7 ± 0.1
 LV Stroke volume (mL) 92.2 ± 14.5
 LV Ejection Fraction (%) 58.6 ± 5.1
 Cardiac index (L/min * m−2) 2789.9 ± 438.8
 E peak filling rate (mL/s) 412.1 ± 82.3
 E-decpeak (mL/s2*10−3) − 3.4 ± 1.0
 E-decmean (mL/s2*10−3) − 2.2 ± 0.7
 E/A peak flow 1.1 ± 0.3
 E/Ea 10.6 ± 4.6
 Neutral lipid content (%) 0.8 ± 0.5
Table 7.  Characteristics of the study population (Validation Study). Data are presented as mean ± SD for 
continuous variables and as frequencies (percentages) for categorical variables. *Statistically significant. ACE: 
Angiotensin-converting enzyme; ARB: angiotensin receptor blocker; HbA1c: Glycated haemoglobin. For other 
abbreviations see the text.
β P-value
E/A peak flow
 LIPCAR − 0.593 0.001*
LVMV-ratio
 MIAT 0.471 0.009*
 SENCR 0.421 0.021*
Table 8.  Association between LV diastolic function/remodelling and circulating lncRNAs in patients with 
well-controlled type 2 diabetes (Validation Study). *Statistically significant.
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Myocardium In Diabetes) study5, a prospective multicentre study designed to evaluate the effect of pioglitazone 
on myocardial function in 78 patients with well-controlled type 2 diabetes of short duration and with verified 
absence of structural heart disease or inducible ischemia. Men with uncomplicated type 2 diabetes aged 45 to 65 
years were eligible. Patients were recruited by advertisement in local newspapers. The inclusion criteria were as 
follows: (i) glycated haemoglobin (HbA1c) level between 6.5% and 8.5%; (ii) BMI between 25 and 32 kg/m2; (iii) 
SBP < 150 mmHg/DBP < 85 mmHg, with or without the use of antihypertensive drugs. The exclusion criteria 
were: (i) any clinically significant disorder, particularly any history or complaints of cardiovascular or liver dis-
ease, or diabetes-related complications, including proliferative retinopathy, autonomic neuropathy, as excluded 
by Ewing’s test32, microalbuminuria, as excluded by determination of urine albumin/creatinine ratio, substance 
abuse and all contraindications to MRI; and (ii) prior use of thiazolidinediones or insulin. High-dose dobutamine 
stress echocardiography was performed to exclude cardiac ischemia or arrhythmias. The 78 patients were ran-
domly distributed between the initial (N = 48) and validation groups (N = 30). Randomization was blinded to 
patient characteristics. Differences in age, waist circumference, plasma fasting glucose and diuretic use were 
observed between initial and validation groups (Supplementary Table S4).
Serum samples from 12 male control volunteers within the same range of age (45–65 years) were obtained 
from a previous study19. As the patient group these subjects were recruited by advertisements in the local news-
papers. Control subjects were required to fulfil the following inclusion criteria: no known acute or chronic dis-
ease based on medical history, physical examination and standard laboratory tests (blood counts, fasting blood 
glucose, lipids, serum creatinine, liver enzymes and electrocardiogram). Exclusion criteria were as follows: 
(i) chronic use of any drug; (ii) substance abuse; (iii) hypertension; (iv) impaired glucose tolerance (as excluded 
by a 75-g oral glucose tolerance test). The study was performed at two institutes in The Netherlands (Leiden 
University Medical Center, Leiden, and Vrije Universiteit Medical Center, Amsterdam) and approved by both 
local ethics committees. Written informed consent was obtained from all participants. This study was performed 
in full compliance with the Declaration of Helsinki.
Blood sampling, study procedures and laboratory analyses have been previously described5,19,33.
Magnetic resonance imaging. MR assessments in both study groups were performed at a single site 
(Leiden) using a 1.5-T whole-body MR scanner (Gyroscan ACS/NT15; Philips, Best, the Netherlands). The entire 
heart was imaged in the short-axis orientation with ECG-gated breath-hold balanced steady state free-precession 
imaging34. The following measures of cardiac dimensions were determined: LV mass; LV end-systolic volume; LV 
end-diastolic volume; and stroke volume. LV mass/volume ratio (LVMV-ratio) was calculated as the LV mass to 
LV end-diastolic volume ratio. Measures of systolic function were LV ejection fraction and cardiac index (car-
diac output/body surface area). An ECG-gated gradient echo sequence with velocity encoding was performed to 
measure blood flow across the mitral valve to determine LV diastolic function parameters, including peak filling 
rates of the early filling phase (E), atrial contraction (A) and the E/A ratio. Peak (E-decpeak) and mean (E-decmean) 
deceleration gradients of the E wave were also calculated34. LV filling pressures (E/Ea) were estimated35. Diastolic 
function was classified according to current European Association of Echocardiography and American Society 
of Echocardiography guidelines21. Patients were divided into 2 categories: normal diastolic function and grade I 
diastolic dysfunction groups, after ruling out the presence of pseudonormal or restrictive patterns. Images were 
analysed quantitatively using dedicated software (MASS and FLOW, Medis, Leiden, the Netherlands).
RNA isolation and quantification of lncRNAs. LncRNA quantitative analysis was restricted to a panel 
of 12 lncRNAs previously associated with cardiovascular disease and/or diabetic conditions. Specifically, we ana-
lysed LIPCAR, uc004cos.4, uc004cov.4, uc004coz.1, uc011mfi.2, uc022bqu.1 and uc022bqw.1, all of which have 
been associated with LV remodelling post myocardial infarction13. These lncRNAs are of mitochondrial origin 
and are therefore highly expressed in the heart10. MALAT1 and MIAT have been implicated in microvascular 
complications of DM15,16. Notably, MALAT1 regulates hyperglycaemia-induced inflammation in endothelial 
cells36 and MIAT participates in the signaling pathway for high glucose-induced renal tubular epithelial injury37. 
Circulating MALAT1 and MIAT are univariate predictors of LV dysfunction after MI14. Circulating MALAT1 
was associated with DM in MI patients14. Although a causal relationship has not been established, genetic vari-
ation in MIAT has been proposed as a risk factor for MI38. H19 has been implicated in the control of metabolic 
alterations induced by type 2 diabetes39 and upregulation of cardiac H19 expression has been reported in a mouse 
model of HF40. HOTAIR is implicated in aortic valve calcification41. Finally, SENCR has been proposed as a 
vascular-enriched lncRNA involved in the control of smooth muscle cell phenotype29. SENCR is highly expressed 
in tissues enriched in human smooth muscle cells and endothelial cells, including the heart29.
Total RNA extraction was performed from serum samples (200 μ l) using miRNeasy Serum/Plasma Kit 
(Qiagen), according to the manufacturer’s instructions. Synthetic Caenorhabditis elegans miR-39-3p (cel-miR-
39-3p) was added as an external standard (1.6 × 108 copies/μ L). Cel-miR-39-3p was spiked into samples during 
RNA isolation after incubation with the denaturing solution. Quality of the isolated RNA was evaluated using 
Agilent 2100 Bioanalyzer (Agilent Technologies). We have previously demonstrated that extracellular lncRNA 
are stably detected with no effect of room temperature (up to 24 hours) or repetitive freeze/thaw cycles (four 
cycles)13. cDNA was synthesized using the iScrip select cDNA synthesis kit (Bio-Rad). LncRNAs were analysed by 
amplification via RT-qPCR (iQ™ SYBR® Green Supermix, Bio-Rad) using a CFX-384 Bio-Rad machine. Primer 
sequences of the lncRNAs analysed are shown in Supplementary Table S5. The NCBI browser (http://www.
ncbi.nlm.nih.gov/tools/primer-blast/), Primer 3 (http://primer3.ut.ee/) and Oligo Calc (http://biotools.nubic.
northwestern.edu/OligoCalc.html) were used to design primers for the specific lncRNAs. The primer sequences 
for LIPCAR, uc004cos.4, uc004cov.4, uc004coz.1, uc011mfi.2, uc022bqw.1 and uc022bqu.1 were previously 
described by our group13. Specific primer sequences for MIAT42 and SENCR29 were also described previously. 
The detection of specific lncRNAs was validated by conventional PCR and agarose gel electrophoresis. Optimal 
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annealing temperature was tested and optimized in advance for each primer pair. The CFX Manager 3.1 software 
(Bio-Rad) was used for both the determination of the threshold cycle (Ct) and for the melting curve analysis. The 
Ct was defined as the fractional cycle number at which the fluorescence exceeded a given threshold. The specific-
ity of the PCR reaction was evaluated by melting curve analysis. LncRNA were considered to be expressed when 
Ct values were less than 39 and were detected with 3 Ct less than the negative control. This approach has been 
previously used in the field of circulating non-coding RNAs as potential clinical biomarkers43. LncRNAs in which 
80% of the samples did not meet these criteria were considered to be below the limit of detection. The normaliza-
tion control cel-miR-39 was amplified by specific TaqMan assay (Applied Biosystems). We have previously used 
this approach for blood-based lncRNAs13,44. Relative quantification was performed using the 2−dCt method, where 
dCt = mean Cttarget − mean Ctcel-miR-39.
Statistical analysis. Data are presented as mean ± SD for continuous variables and as frequencies (percent-
ages) for categorical variables. Data normality was evaluated using the Kolmogorov-Smirnov test. Non-normally 
distributed variables (circulating lncRNAs, heart rate, fasting plasma glucose, plasma triglycerides, us-CRP and 
NT-proBNP) were logarithmically transformed to account for nonlinearity. Continuous variables were compared 
between groups using a Student’s t-test for independent samples. Circulating lncRNA expression levels were also 
adjusted for BMI and SBP with ANCOVA models to account for differences between type 2 diabetes and control 
groups. Correlations between variables were analysed using Pearson’s correlation analysis and the results pre-
sented using Pearson’s correlation coefficient (ρ ). Linear regression analyses were performed to detect associations 
between clinical characteristics or cardiac MRI parameters and lncRNA expression. To identify independent pre-
dictors of cardiac function and remodelling in multivariate analyses, E/A peak flow or LVMV-ratio were entered 
into the models used as a dependent variable and circulating lncRNAs, age and BMI were subsequently entered 
as independent variables (model 1). In addition, possible confounding variables such as plasma fasting glucose, 
plasma fasting insulin, time since diagnosis of diabetes, SBP, DBP, heart rate, myocardial steatosis, us-CRP and 
NT-proBNP were separately entered into the model 1 (model 2). Results are expressed as standardized beta (β) 
coefficients. Logistic regressions were analysed to explore the association between circulating lncRNAs and 
diastolic dysfunction as outcome. Diastolic dysfunction was entered as a dependent variable and subsequently, 
circulating lncRNAs, age and BMI were as independent variables (model 1). In order to establish whether the 
observed association between diastolic dysfunction and circulating lncRNAs expression levels could be influ-
enced by possible confounders, model 1 was also adjusted for plasma fasting glucose, plasma fasting insulin, time 
since diagnosis of diabetes, SBP, DBP, heart rate, myocardial steatosis, us-CRP or NT-proBNP (model 2). The 
results are presented as the odds ratio (OR) and 95% confidence intervals (CI). The AUC was analysed to explore 
the accuracy of the logistic regression models. All potential confounding factors were selected based on previous 
observations from our group and others19,45, or results observed in current investigation. Values of P < 0.050 were 
considered statistically significant. All statistical analyses were performed using the statistical software package 
SPSS 15.0 for Windows (SPSS Inc).
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